Compare MINISO Group Holding Ltd (MNSO) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MINISO Group Holding Ltd vs Summit Therapeutics Inc — how do they compare? MINISO Group Holding Ltd trades at $11.91 (market cap $3.62B), while Summit Therapeutics Inc trades at $15.05 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 3.3× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays a 5.53% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MNSO | SMMT | |
|---|---|---|
Market Cap | $3.62B | $12.06B |
Sector | Technology | Health |
52-Week High | $26.63 | $26.98 |
52-Week Low | $11.30 | $12.55 |
Enterprise Value | $4.29B | $11.39B |
Dividend Yield | 5.53% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MNSO trades at $11.895, down 4.99% in the last session amid a neutral technical outlook. Recent earnings show volatility with a Q1 2026 beat but Q3 and Q4 2025 misses, while fundamentals reveal solid revenue growth to $21.44 billion in 2025 and a net income margin of 8.98%. The company announced a $2 billion share repurchase program in June 2026, signaling confidence.
The stock presents a mixed outlook: valuation ratios like P/E of 12.16 appear reasonable, and analyst consensus is 75% buy, but risks include margin pressure from SG&A growth and competitive retail dynamics. Near-term price action hinges on Q2 2026 earnings delivery against expectations of $0.2754 EPS.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
